Welsh restrictions on LGBT stem cell donation to be lifted attitude.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from attitude.co.uk Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced today that the Company has nominated a lead.
LMNL6326 nominated as lead preclinical candidate for OXER1 antagonist development program, targeting the treatment of eosinophil-driven diseasesAdvancement of clinical trial application (CTA)
Liminal BioSciences (LMNL) Provides R&D Update streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
CTA-enabling work on track to seek approval to commence Phase 1 clinical trial of LMNL6511 during the second half of 2023 Addition of GPR40 agonist discovery.